Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 8/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174617 | 0.84 | HTT (0.46) | KEAP1NFE2L2HTTGPR88PTGIR | |
| SCHEMBL6172831 | 0.82 | KEAP1 (0.44) | KEAP1NFE2L2HTTGPR88PTGIR | |
| SCHEMBL6171439 | 0.82 | ALDH1A1 (0.50) | KEAP1NFE2L2HTTGPR88PTGIR | |
| SCHEMBL6176749 | 0.81 | CHRM5 (0.51) | KEAP1NFE2L2PTGIRACHEOPRM1 | |
| SCHEMBL6170917 | 0.81 | KEAP1 (0.43) | KEAP1NFE2L2HTTPTGIRTSHR | |
| SCHEMBL6175650 | 0.75 | STS (0.54) | HTT | |
| SCHEMBL14000153 | 0.75 | CNR2 (0.44) | HTTOPRM1 | |
| SCHEMBL7106756 | 0.72 | KEAP1 (0.55) | KEAP1NFE2L2TSHRACHE | |
| SCHEMBL4598838 | 0.72 | GPR88 (0.48) | HTTGPR88OPRM1HSP90AA1 | |
| SCHEMBL18930910 | 0.72 | RNF4 (0.60) | HTTACHEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | KEAP1 4651/4885NFE2L2 2014/4885HTT 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.